Shenaz Bagha

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs.

WASHINGTON — A focus on patient follow-up, standardized medication adherence and barriers assessments can reduce racial and ethnic disparities in juvenile idiopathic arthritis, according to a speaker at ACR Convergence 2024.

Hypertension, atrial fibrillation and smoking were most strongly associated with an increased risk for severe compared with non-severe stroke, according to analysis from the INTERSTROKE study.

WASHINGTON — Exposure to specific pesticides, including DDT, demonstrates “strong and significant” risks for rheumatoid arthritis among the female

WASHINGTON — Addressing economic insecurities through a social worker “could improve” physical function and other patient reported outcomes in systemic lupus erythematosus, according to a speaker at ACR Convergence 2024.

WASHINGTON — Children with lupus from areas of lower socioeconomic opportunity experience more severe disease complications and poorer outcomes than

For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved staggered regimen of the drug plus placebo, according to a poster presented at AANEM.

WASHINGTON — Although even low-dose prednisone significantly increases the risk for fracture in systemic lupus erythematosus, there is no increased

WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis, including

WASHINGTON — Addressing burnout in rheumatology will require attention to personal exhaustion and depersonalization, as well as systemic business-of-medicine issues, according to a speaker at ACR Convergence 2024.